Howson zooms in! 8 new products were approved, 16 varieties of the first review, 9 varieties to grab the first imitation, 3 1 class of new drugs to be released

Recently, Howson Pharmaceuticals' first innovative drug declared clinical in 2021, targeting $4.6 billion star drug.
In 2020, Howson Pharmaceuticals has won eight new products (including 2 innovative drugs, 3 first imitations), 3 new Class 1 drugs into new health insurance, 2 innovative drugs applied for market (including 1 New Class 1 drug), and 5 innovative drugs were approved clinically (including 3 Class 1 new drugs).
Hausen Pharmaceuticals currently has 22 varieties over-evaluated (16 for the first), 4 varieties included in the fourth batch of harvesting;
took 8 heavy-duty new products, 3 new drugs 1 into the new health insurance Mienet data show that in terms of status start time, a total of 8 new products approved for market in 2020, covering anti-tumor, type 2 diabetes, neurological diseases three major therapeutic areas, one of which is a new class of drugs, one for improved new drugs, three for the first generic drugs.
2020 Howson Pharmaceuticals Newly Approved Products Source: MED2.0 China Drug Review Database Innovation Power. Class
1 new drug methulphate amethystini is the third generation of EGFR inhibitors developed by Hausen Pharmaceuticals, and the first domestic third generation EGFR inhibitors;
focus on the first imitation.
Malay acid afatini is a second-generation EGFR inhibitor developed by Grigg Ingham, with sales of more than 200 million yuan at public medical facilities in China in the first half of 2020, up 153.87 percent year-on-year; Antipsychotics, with global sales of $3.33 billion in 2019, and Ingley Net, a highly selective SGLT-2 inhibitor developed jointly by Lilly and Grigg Ingham, will have global sales of more than $3 billion in 2019.
December 28, 2020, the results of the much-anticipated 2020 National Health Care Directory negotiations were announced, with 119 new drugs added to the list, of which 96 exclusive drugs were negotiated and 23 non-exclusive drugs were transferred directly.
Haussen Pharmaceuticals has four new products into health insurance, of which three exclusive varieties (all of which are new class 1 drugs) for negotiation transfer, 1 generic drug for direct transfer.
table 2: Howson Pharmaceuticals into the new version of health insurance products Source: Minet China health insurance catalog database polyglycol losenathe is Howson Pharmaceuticals developed the first domestic long-acting GLP-1 perturbation agent, but also the world's first PEG-based long-acting GLP-1 patient excitant, in May 2019 to obtain production approval.
the 2020 minimum list price/winning bid compared to the 2020 Medicare payment standard, the product's 0.5ml:0.1mg specification decreased by 62.7% and the 0.5ml:0.2mg specification decreased by 52.7%.
is the first domestically produced new second-generation BCR-ABL tyrosine kinase inhibitor (TKI), and Howson Pharmaceuticals received production approval in December 2019.
the 2020 minimum list price/winning bid compared to the 2020 Medicare payment standard, the product's 0.2g specification fell by 63%.
is the new drug approved for sale in 2020, making it one of the 16 "lucky people" (the "seamless interface" between drug approval and medicare review) that are fast entering the national health insurance list.
the lowest list price/winning bid for the product in 2020 is 176 yuan (55mg/piece), in line with the 2020 health insurance payment standard.
16 varieties of the first review, 9 varieties to grab the first imitation table 3: Howson Pharmaceuticals has been evaluated varieties Source: MED2.0 China Drug Review Database Minenet data show that there are currently 22 varieties of Howson Pharmaceuticals through or As the same through the consistent evaluation, of which 16 were the first to be evaluated, injection with gistatin hydrochloric acid, injection with cyclocycline, palicide ketone slow release tablets, injection with Fusapitan double glucosamine 4 varieties for exclusive evaluation.
fourth batch of national collections was officially launched on January 15th and opened on February 3rd.
of the 45 generic drugs, Howson Pharmaceuticals has four varieties have been evaluated, respectively, injection of boron zomi, reglinai tablets, Engele net tablets, Kagele net tablets, in addition to injection boron tezome (4 over-reviewed), the remaining 3 varieties of over-evaluation enterprises are only 2, the competitive landscape is good.
Table 4: Howson Pharmaceuticals Consistency Evaluation in Review (including New Classification) Source: MED2.0 China Drug Review Database Howson Pharmaceuticals in ReviewEd Varieties, 6 Varieties Submit Consistent Evaluation Supplemental Applications, In addition to injection-based bivaldide, hydrochloric acid Dornasi tablets, the remaining 4 varieties have not yet been evaluated by enterprises; The new classification was reported, in which 9 varieties of acetate carbalin tablets, ezalumin softgels, lulasitone tablets of hydrochloric acid, tarant acid valenicron tablets, right lansolazole intestinal capsules, hydrobrominate voltsitin tablets, cider acid cabotinib tablets, acetic acid aetamine injections, and 9 varieties of Tiraros tablets were approved for the market without imitation.
injections with kafezome, Nzaluamine softgels, and Tiraros tablets were exclusively produced by Howson Pharmaceuticals in a new classification.
Kafezome is the second-generation protease inhibitor developed by Amgen, with global sales of more than $1 billion in 2019, and the original product is being imported; Body signal conduction inhibitors, original research products approved for import at the end of 2019, Tiraros is Novartra's iron chelating agent products, is the FDA approved the first conventional use of oral iron repellent, the original research has not been approved for import.
2 innovative drugs declared on the market, attacking $4.6 billion star drug January 6, Haussen Pharmaceuticals subsidiary Shanghai Henson Bio submitted the first clinical application for innovative drugs in 2021, for class 3.3 new drugs recombinant anti-RANKL all-human source monoclonal antibody injection, the product is Denosumab bio-like drugs.
is the world's first RANKL single resistance developed by Amgen, with global sales of $4.61 billion in 2019.
Table 5: 2020-present Howson Pharmaceuticals Declares Listed/Clinical Innovative Drugs Source: MED2.0 China Drug Review Database 2020, Howson Pharmaceuticals has 2 innovative drug applications on the market, Inebilizumab Injection is the company and Vila Bio, Inc., an innovative drug jointly developed and commercialized in China, has been approved by the FDA for listing, is the first reported anti-CD19 monoantigen; Amphenol amine novovir tablets are the company's own research and development of nucleoside reverse transcriptase inhibitors, is a new type of anti-novovir drugs that can improve efficacy and reduce toxic side effects, is expected to become the company's fifth approved listed class 1 new drug.
amethytic tablets (new adaptation), HS-10353 capsules, HS-10356 tablets, HS-10352 tablets, HS-20090 injection applications for clinical and have been approved clinically.
3 new class 1 drugs HS-10353 capsules, HS-10356 tablets, HS-10352 tablets are used to treat depression, non-alcoholic fatty hepatitis, advanced breast cancer.